A Letter from Hervé
To Our Stakeholders,
At Incyte, patients have always been our driving force, inspiration and motivation. For more than 20 years, we have followed science in search of solutions that can improve the lives of patients in need. Our shared purpose flows through everything we do, starting with our exceptional team who works side-by-side each day tackling new areas of drug discovery and development. This approach has resulted in another year of success that builds on our mission.
In 2021, our commercial portfolio expanded significantly with regulatory approvals and expanded indications for our medicines globally. This notably includes multiple “firsts,” such as the first topical formulation of a JAK inhibitor approved in the U.S. and the first targeted therapy approved in Europe, Japan and Canada for a type of cancer that begins in the bile duct. An Incyte-discovered medicine also received an expanded Emergency Use Authorization (EUA) in the U.S. to support the treatment of hospitalized COVID-19 patients requiring oxygen—another critical step in the fight against the pandemic.
Across our marketed products, we saw total product and royalty revenues of $2.89 billion in 2021, a 17% increase over 2020. We also continued to advance both early- and late-stage research supporting our robust and diversified pipeline of medicines across myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD), General Hematology/Oncology, Dermatology and other Inflammation & Autoimmunity (IAI).
At the same time, the pandemic continued to present unprecedented global challenges that required the full strength of our resources and expertise. We took steps to ensure that patients received the care they need by adapting our processes, putting systems in place to ensure our supply chain remained uninterrupted and maintaining the continuity of our ongoing clinical trials.
To be the company that we want to be now and in the future, our commitments must extend beyond regulatory and business milestones, and ensure every step we take in some way empowers our team, considers sustainability and protection of the environment and uplifts our communities. With this, I am excited to share our 2021 Global Responsibility Report and the advancements we have made toward achieving our corporate environmental, social and governance goals.
Some of our most notable progress over the past year focused on minimizing the environmental footprint of our physical locations. Specific to our U.S. headquarters in Wilmington, DE, we achieved Green Globes certification for Building 1815 and now operate all buildings with 100% renewable energy. We also opened our manufacturing facility in Yverdon-les-Bains, Switzerland, with advanced environmental programs. Additionally, for the first time, we included ESG factors as part of our 2022 annual bonus goals to deepen our commitment and demonstrate how important these objectives are to our overall success as an organization.
Just as our presence expands around the world, so too does our responsibility to create sustainable access to our medicines for patients.
I will close by saying, together, we are taking steps to advance our Global Responsibility strategy in a way that we believe will support meaningful change—not only for Incyte and our stakeholders, but also for patients in the years to come. We at Incyte want to thank you for your ongoing support of our ESG commitments and we look forward to sharing our continued progress with you.
Chief Executive Officer